{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-007845","form_type":"8-K","ticker":"RXST","cik":"0001111485","company_name":"RxSight, Inc.","filed_at":"2022-05-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:59.790476+00:00","generated_at":"2026-06-25T23:20:33.179913+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"RxSight Q1 revenue up 157% to $8.9M; raises 2022 revenue guidance","bullets":["Revenue $8.9M (+157% YoY); LDD sales 40 units (+208%), installed base 246 (+134%).","Net loss $17.6M ($0.64/share); adjusted net loss $14.9M ($0.54/share).","2022 revenue guidance raised to $41.5-45.5M from $40-44M, implying 84-101% annual growth.","Amended Oxford Finance loan: extends draw periods for remaining $20M, interest-only period to 2025.","Procedure volumes: 4,166 LALs sold (+166% YoY)."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-007845","json":"https://secwatch.observer/filing/0000950170-22-007845.json","markdown":"https://secwatch.observer/filing/0000950170-22-007845.md","text":"https://secwatch.observer/filing/0000950170-22-007845.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1111485/000095017022007845/0000950170-22-007845-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1111485/000095017022007845/rxst-20220505.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T23:20:33.179913+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}